Results 161 to 170 of about 76,161 (283)

Transcatheter arterial embolization combined with hypoxia-replicative oncolytic adenovirus perfusion enhances the therapeutic effect of hepatic carcinoma

, 2019
Hongsen Zhang, Fu Xiong, Kun Qian, Yiming Liu, Bin Liang, Bin Xiong, Fan Yang, Chuansheng Zheng Department of Radiology, Union Hospital of Tongji Medical College, Huazhong University of Science and Technology, Wuhan, China Purpose: Transcatheter arterial
Liu Y, Zhang H, Zheng C, Xiong B, Xiong F, Qian K, Yang F, Liang B   +7 more
core  

Efficacy and Safety of Catheter Ablation in Very Elderly Patients With Atrial Fibrillation: Short‐ To Mid‐Term Outcomes From a Multicenter Study

Journal of Arrhythmia, Volume 42, Issue 3, June 2026.
Patients aged ≥ 80 years with atrial fibrillation underwent catheter ablation. At 2 years, the recurrence‐free survival rate was 85.8% in paroxysmal AF and 63.6% in persistent AF (p = 0.024), and periprocedural complications occurred in 12.0%, including severe complications in 3.3%.
Takumi Tamura, Yoshihisa Naruse, Taro Narumi, Yuki Tokonami, Yasukazu Takazawa, Kazuki Ito, Yutaro Kaneko, Makoto Sano, Ryosuke Takeuchi, Natsuko Hosoya, Masahiro Muto, Ryuta Henmi, Ryo Sugiura, Keisuke Miyajima, Yuichiro Maekawa   +14 more
wiley   +1 more source

Management of Bioprosthetic Valve Thrombosis Following Transcatheter Mitral Valve Replacement. [PDF]

JACC Case Rep
Davidson N, Murdoch D, Gurvitch R.
europepmc   +1 more source

Left Bundle Branch Area Pacing vs. Biventricular Pacing for Cardiac Resynchronization: Propensity Score Analysis

Journal of Arrhythmia, Volume 42, Issue 3, June 2026.
In this two‐center propensity score–weighted cohort of de novo CRT recipients, left bundle branch area pacing was associated with comparable resynchronization and clinical outcomes to biventricular pacing, with fewer late device‐related complications. ABSTRACT Background Left bundle branch area pacing (LBBAP) has emerged as a promising alternative to ...
Fawzi Kerkouri, Pierre Khattar, Vincent Mansourati, Laurent Palud, Jean Baptiste Moreau, Hugo Hager, Jean Philippe Hacot, Florent Le Ven, Jacques Mansourati   +8 more
wiley   +1 more source

Real‐World Comparison of Vascular Access Closure Strategies in TAVI

Catheterization and Cardiovascular Interventions, Volume 107, Issue 7, Page 2150-2152, June 1, 2026.
Saif Zako, Kathrin Klein, Karin Alde, Christian Jung, Verena Veulemanns, Maximilian Scherner, Artur Lichtenberg, Malte Kelm, Tobias Zeus, Amin Polzin   +9 more
wiley   +1 more source

Current Topics of Progressive Cardiac Conduction Disease

Journal of Arrhythmia, Volume 42, Issue 3, June 2026.
Many genes and the protein cause PCCD. Mutation of NaV1.5 or CX40 cause isolated PCCD, but mutation of lamin A/C, emerin, or desmin lead to cardiomyopathy, and PCCD. Mutation of transcription factor NCX2‐5, and Tbx5 associated with atrial septal defect and abnormal development of conduction system.
Naokata Sumitomo, Hitoshi Mori, Takashi Kumamoto, Taisuke Ishikawa, Akiko Seki, Naomasa Makita, Jean‐Jacques Schott, Arthur A. M. Wilde   +7 more
wiley   +1 more source

Treatment of Acute M3 Thrombosis. [PDF]

JACC Case Rep
Syed BH, Pink K, Sunner GK, Hull R, Worku B, Perk G, Ramasubbu K, Jones MM, Rong L, Chan M, Reisman M, Mihatov N.   +11 more
europepmc   +1 more source

Atrial Leadless Pacemaker Embolization to the Left Common Iliac Vein With Successful Retrieval: A Case Report

Journal of Arrhythmia, Volume 42, Issue 3, June 2026.
A rare extracardiac complication in which a dislodged atrial leadless pacemaker migrated retrogradely to the left common iliac vein. This case highlights the role of venous anatomy in implantation difficulty and demonstrates successful device retrieval using a preventive strategy.
Toshihiko Goto, Masashi Yokoi, Yoshiro Tsuruta, Kento Mori, Yoshihiro Seo   +4 more
wiley   +1 more source

Transcatheter mitral valve replacement after transcatheter direct annuloplasty with Cardioband

European Heart Journal, 2019
Pozzoli A, Gavazzoni M, Maisano F, Taramasso M   +3 more
openaire   +4 more sources

Impact of Frequent Immune‐Mediated Adverse Events on Treatment Continuity and Outcomes During Durvalumab Plus Tremelimumab Therapy for Unresectable Hepatocellular Carcinoma

Liver International Communications, Volume 7, Issue 2, June 2026.
ABSTRACT Durvalumab plus tremelimumab (Dur/Tre) is the first‐line treatment for unresectable hepatocellular carcinoma (uHCC). Immune‐mediated adverse events (imAEs) are common; however, the impact of specific imAE types on treatment persistence and outcomes remains unclear.
Tomomitsu Matono, Toshifumi Tada, Atsushi Hiraoka, Masashi Hirooka, Kazuya Kariyama, Joji Tani, Masanori Atsukawa, Koichi Takaguchi, Ei Itobayashi, Shinya Fukunishi, Kunihiko Tsuji, Toru Ishikawa, Kazuto Tajiri, Hironori Tanaka, Hidenori Toyoda, Chikara Ogawa, Takashi Nishimura, Takeshi Hatanaka, Satoru Kakizaki, Kazuhito Kawata, Atsushi Naganuma, Hisashi Kosaka, Hidekatsu Kuroda, Yutaka Yata, Hiroki Nishikawa, Michitaka Imai, Tomoko Aoki, Hironori Ochi, Hideyuki Tamai, Shohei Komatsu, Hideko Ohama, Fujimasa Tada, Shinichiro Nakamura, Kazuhiro Nouso, Asahiro Morishita, Norio Itokawa, Tomomi Okubo, Taeang Arai, Akemi Tsutsui, Takuya Nagano, Kazunari Tanaka, Takanori Matsuura, Yoshihide Ueda, Yuichi Koshiyama, Yuki Kanayama, Hidenao Noritake, Hirayuki Enomoto, Kosuke Matsui, Masaki Kaibori, Takumi Fukumoto, Yoichi Hiasa, Masatoshi Kudo, Takashi Kumada, on behalf of the RELPEC Group and HCC 48 Group   +53 more
wiley   +1 more source